Want to see MDAI full AI Analyst Report?
MDAI Stock Chart & Stats
$1.61
$0.02(1.22%)
At close: 4:00 PM EDT
$1.61
$0.02(1.22%)
Day’s Range― - ―
52-Week Range$1.18 - $2.97
Previous CloseN/A
Volume35.05K
Average Volume (3M)272.42K
Market Cap
$50.53M
Enterprise Value$57.78
Total Cash (Recent Filing)$13.98M
Total Debt (Recent Filing)$16.26M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 17, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding32,184,930
10 Day Avg. Volume290,415
30 Day Avg. Volume272,420
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-6.58
Price to Sales (P/S)1.92
P/FCF Ratio-3.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside148.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$18.55M
Bulls Say, Bears Say
Bulls Say
FDA Clearance Enables DeepView CommercializationFDA de novo clearance removes a major regulatory barrier and validates the burn-care application. It enables U.S. commercialization, supports hospital adoption discussions, and creates a foundation for future indications and international expansion.
Substantial Non-dilutive Funding Supports RolloutGovernment-backed funding can finance deployments, clinical work, and product development without immediate equity dilution. Planned BARDA-supported installations also provide an important pathway to build reference sites and accelerate commercial adoption.
Recurring Software Model And Platform Expansion PotentialA device-plus-recurring-services model could make revenue more durable than one-time hardware sales as installations scale. The existing imaging library and planned additional indications provide a basis for expanding DeepView across wound-care markets.
Bears Say
Revenue Remains Weak And Dependent On Development ContractsDeclining revenue and lower R&D contract income show that the historical funding-driven model is weakening before commercial sales are established. The transition creates uncertainty over whether DeepView adoption can replace lost development revenue.
Stressed Balance Sheet And Continued Cash BurnNegative equity, rising debt, and substantial cash burn limit financial flexibility and indicate that operations are not yet self-funding. Continued commercialization investment may require external financing, increasing dependence on facilities and government support.
Margin Pressure And Commercialization Execution RiskLower margins and higher expenses could persist while the company shifts from development work to commercial deployment. Excluding meaningful device sales from guidance highlights uncertainty around procurement cycles, sales capacity, pricing, and the timing of recurring revenue.
Spectral AI News
MDAI FAQ
What was Spectral AI’s price range in the past 12 months?
Spectral AI lowest stock price was $1.18 and its highest was $2.97 in the past 12 months.
What is Spectral AI’s market cap?
Spectral AI’s market cap is $50.53M.
When is Spectral AI’s upcoming earnings report date?
Spectral AI’s upcoming earnings report date is Nov 17, 2026 which is in 78 days.
How were Spectral AI’s earnings last quarter?
Spectral AI released its earnings results on Aug 11, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.135 by $0.005.
Is Spectral AI overvalued?
According to Wall Street analysts Spectral AI’s price is currently Undervalued.
Does Spectral AI pay dividends?
Spectral AI does not currently pay dividends.
What is Spectral AI’s EPS estimate?
Spectral AI’s EPS estimate is -0.14.
How many shares outstanding does Spectral AI have?
Spectral AI has 32,184,930 shares outstanding.
What happened to Spectral AI’s price movement after its last earnings report?
Spectral AI reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.135. Following the earnings report the stock price went down -8.187%.
Which hedge fund is a major shareholder of Spectral AI?
Currently, no hedge funds are holding shares in MDAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spectral AI Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (148.45% Upside)
$4.00 (148.45% Upside)
Blogger Sentiment
Bearish
MDAI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 100.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Spectral AI
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient’s wounds. Its system also includes MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images; and AI-Burn software. Spectral AI, Inc. is headquartered in Dallas, Texas.
MDAI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a major strategic and clinical milestone with FDA de novo clearance and substantial non-dilutive government support, creating a strong foundation for commercialization. Financial indicators show improvement in adjusted EBITDA and narrower net loss, plus access to committed capital and BARDA funding that support the near-term launch. However, short-term revenue mix and margins are compressed by BARDA cost-share, R&D revenue declined ~31%, operating expenses rose, and commercialization faces execution risks (limited current salesforce, procurement and regulatory timelines). On balance, the company appears positioned for a constructive commercial transition, but near-term financials and execution risks temper the outlook.View all MDAI earnings summariesMDAI Stock 12 Month Forecast
Average Price Target
$4.00
▲(148.45% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
9.99% Insiders
3.44% Mutual Funds
4.67% Other Institutional Investors
78.56% Public Companies and
Individual Investors